pharmatechoutlook

3D Printed Drug by Aprecia Pharmaceuticals Gets a Nod from the FDA

By Pharma Tech Outlook | Friday, November 30, 2018

FREMONT, CA: Aprecia Pharmaceutical’s SPRITAM drug has recently got approval from the U.S. Food and Drug Administration (FDA) for the treatment of epilepsy. The drug is manufactured using 3D printing technology and the company claims that it is the first 3D printed drug ever to be approved by the FDA.

Mike Murphy from qz.com writes that the new tablet is made by 3D-printing layers of powdered drug, binding the layers of powder together, and then blowing away the excess powder. The drug’s unique structure allows it to dissolve considerably faster than the average pill, which as the news site 3DPrint points out is a boon to seizure sufferers who often are prescribed large, hard-to-swallow pills. Aprecia also says 3D printing will allow doctors to know that the medicine they’re prescribing delivers the exact dose intended, as each pill will be completely uniform.

“By combining 3-D printing technology with a highly-prescribed epilepsy treatment, SPRITAM is designed to fill a need for patients who struggle with their current medication experience,” says Don Wetherhold, CEO, Aprecia. “This is the first in a line of central nervous system products Aprecia plans to introduce as part of our commitment to transform the way patients experience taking medication.”

Robert J. Szczerba writing for Forbes says that 3-D printing of medications will allow doctors to know that the medicine they are prescribing delivers the exact dose intended, as each pill will be completely uniform and tailored for the individual patient. Such a capability, he believes will open the door to a number of fascinating distribution options as well, including the eventual possibility of printing personalized medicine in one’s own home.

New Editions